Search

Your search keyword '"Baggerly, Keith A."' showing total 771 results
Start Over Author "Baggerly, Keith A."
771 results on '"Baggerly, Keith A."'

1. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis

Author

Lee, Sangkyou, Bondaruk, Jolanta, Wang, Yishan, Chen, Huiqin, Lee, June Goo, Majewski, Tadeusz, Mullen, Rachel D., Cogdell, David, Chen, Jiansong, Wang, Ziqiao, Yao, Hui, Kus, Pawel, Jeong, Joon, Lee, Ilkyun, Choi, Woonyoung, Navai, Neema, Guo, Charles, Dinney, Colin, Baggerly, Keith, Mendelsohn, Cathy, McConkey, David, Behringer, Richard R., Kimmel, Marek, Wei, Peng, and Czerniak, Bogdan

Published
2024
Full Text
View/download PDF

2. Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma

Author

Stur, Elaine, Bayraktar, Emine, Dal Molin, Graziela Zibetti, Wu, Sherry Y, Mangala, Lingegowda S, Yao, Hui, Wang, Ying, Ram, Prahlad T, Corvigno, Sara, Chen, Hu, Liang, Han, Tworoger, Shelley S, Levine, Douglas A, Lutgendorf, Susan K, Liu, Jinsong, Moore, Kathleen N, Baggerly, Keith A, Karlan, Beth Y, and Sood, Anil K

Subjects
Cancer, Ovarian Cancer, Genetics, Biotechnology, Rare Diseases, long-term survival, short-term survival, ovarian cancer, HGSC, TMEM62, Oncology and Carcinogenesis
Abstract

Despite having similar histologic features, patients with high-grade serous ovarian carcinoma (HGSC) often experience highly variable outcomes. The underlying determinants for long-term survival (LTS, ≥10 years) versus short-term survival (STS, 2; false discovery rate < 0.01). In the subsequent validation cohort, transmembrane protein 62 (TMEM62) was found to be related to LTS. CIBERSORT analysis showed that T cells (follicular helper) were found at higher levels in tumors from LTS than STS groups. In vitro data using OVCAR5 and OVCAR8 cells showed decreased proliferation with TMEM62 overexpression and positive correlation with a longevity-regulating pathway (KEGG HSA04213) at the RNA level. In vivo analysis using the OVCAR8-TMEM62-TetON model showed decreased tumor burden in mice with high- vs. low-expressing TMEM62 tumors. Our results demonstrate that restoring TMEM62 may be a novel approach for treatment of HGSC. These findings may have implications for biomarker and intervention strategies to help improve patient outcomes

Published
2022

3. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers

Author

Berger, Ashton C, Korkut, Anil, Kanchi, Rupa S, Hegde, Apurva M, Lenoir, Walter, Liu, Wenbin, Liu, Yuexin, Fan, Huihui, Shen, Hui, Ravikumar, Visweswaran, Rao, Arvind, Schultz, Andre, Li, Xubin, Sumazin, Pavel, Williams, Cecilia, Mestdagh, Pieter, Gunaratne, Preethi H, Yau, Christina, Bowlby, Reanne, Robertson, A Gordon, Tiezzi, Daniel G, Wang, Chen, Cherniack, Andrew D, Godwin, Andrew K, Kuderer, Nicole M, Rader, Janet S, Zuna, Rosemary E, Sood, Anil K, Lazar, Alexander J, Ojesina, Akinyemi I, Adebamowo, Clement, Adebamowo, Sally N, Baggerly, Keith A, Chen, Ting-Wen, Chiu, Hua-Sheng, Lefever, Steve, Liu, Liang, MacKenzie, Karen, Orsulic, Sandra, Roszik, Jason, Shelley, Carl Simon, Song, Qianqian, Vellano, Christopher P, Wentzensen, Nicolas, Network, The Cancer Genome Atlas Research, Caesar-Johnson, Samantha J, Demchok, John A, Felau, Ina, Kasapi, Melpomeni, Ferguson, Martin L, Hutter, Carolyn M, Sofia, Heidi J, Tarnuzzer, Roy, Wang, Zhining, Yang, Liming, Zenklusen, Jean C, Zhang, Jiashan, Chudamani, Sudha, Liu, Jia, Lolla, Laxmi, Naresh, Rashi, Pihl, Todd, Sun, Qiang, Wan, Yunhu, Wu, Ye, Cho, Juok, DeFreitas, Timothy, Frazer, Scott, Gehlenborg, Nils, Getz, Gad, Heiman, David I, Kim, Jaegil, Lawrence, Michael S, Lin, Pei, Meier, Sam, Noble, Michael S, Saksena, Gordon, Voet, Doug, Zhang, Hailei, Bernard, Brady, Chambwe, Nyasha, Dhankani, Varsha, Knijnenburg, Theo, Kramer, Roger, Leinonen, Kalle, Miller, Michael, Reynolds, Sheila, Shmulevich, Ilya, Thorsson, Vesteinn, Zhang, Wei, Akbani, Rehan, Broom, Bradley M, Ju, Zhenlin, Li, Jun, Liang, Han, and Ling, Shiyun

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Women's Health, Cancer, Cancer Genomics, Precision Medicine, Genetics, Human Genome, Breast Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Breast Neoplasms, DNA Copy Number Variations, Databases, Genetic, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Genetic Predisposition to Disease, Genital Neoplasms, Female, Humans, Mutation, Organ Specificity, Prognosis, RNA, Long Noncoding, Receptors, Estrogen, Cancer Genome Atlas Research Network, TCGA, The Cancer Genome Atlas, breast cancer, cervical cancer, gynecologic cancer, omics, ovarian cancer, pan-gynecologic, uterine cancer, uterine carcinosarcoma, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

We analyzed molecular data on 2,579 tumors from The Cancer Genome Atlas (TCGA) of four gynecological types plus breast. Our aims were to identify shared and unique molecular features, clinically significant subtypes, and potential therapeutic targets. We found 61 somatic copy-number alterations (SCNAs) and 46 significantly mutated genes (SMGs). Eleven SCNAs and 11 SMGs had not been identified in previous TCGA studies of the individual tumor types. We found functionally significant estrogen receptor-regulated long non-coding RNAs (lncRNAs) and gene/lncRNA interaction networks. Pathway analysis identified subtypes with high leukocyte infiltration, raising potential implications for immunotherapy. Using 16 key molecular features, we identified five prognostic subtypes and developed a decision tree that classified patients into the subtypes based on just six features that are assessable in clinical laboratories.

Published
2018

4. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer

Author

Siedel, Jean H., Ring, Kari L., Hu, Wei, Dood, Robert L., Wang, Ying, Baggerly, Keith, Darcy, Kathleen M., Conrads, Thomas P., Gallagher, Shannon, Tshiaba, Placede, Neff, Chris, Timms, Kirsten M., Mangala, Selanere, Westin, Shannon N., Broaddus, Russell, Lopez-Berestein, Gabriel, Lu, Karen H., Coleman, Robert L., Maxwell, George L., and Sood, Anil K.

Published
2021
Full Text
View/download PDF

5. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach

Author

Lutgendorf, Susan K, Shinn, Eileen, Carter, Jeanne, Leighton, Susan, Baggerly, Keith, Guindani, Michele, Fellman, Bryan, Matzo, Marianne, Slavich, George M, Goodman, Marc T, Tew, William, Lester, Jenny, Moore, Kathleen M, Karlan, Beth Y, Levine, Douglas A, and Sood, Anil K

Subjects
Behavioral and Social Science, Basic Behavioral and Social Science, Rehabilitation, Ovarian Cancer, Mental Health, Cancer, Rare Diseases, Mind and Body, Clinical Trials and Supportive Activities, Clinical Research, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Aged, Carcinoma, Ovarian Epithelial, Cross-Sectional Studies, Disease-Free Survival, Female, Humans, Life Style, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Psychometrics, Quality of Life, Social Support, Survivors, Ovarian cancer, Long-term survivor, Psychosocial, Quality of life, Mood, Lifestyle, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis
Abstract

PURPOSE:Long-term survival of women with advanced-stage ovarian cancer is relatively rare. Little is known about quality of life (QOL) and survivorship concerns of these women. Here, we describe QOL of women with advanced-stage ovarian cancer surviving for 8.5 years or longer and compare women with 0-1 recurrence to those with multiple recurrences. METHODS:Participants (n=56) recruited from 5 academic medical centers and the Ovarian Cancer Research Fund Alliance completed surveys regarding QOL (FACT-O), mood (CESD), social support (SPS), physical activity (IPAQ-SF), diet, and clinical characteristics. Median survival was 14.0 years (range 8.8-33.3). RESULTS:QOL and psychological adjustment of long-term survivors was relatively good, with mean FACT-G scores (multiple recurrences: 80.81±13.95; 0-1 recurrence: 89.05 ±10.80) above norms for healthy community samples (80.1±18.1). Survivors with multiple recurrences reported more compromised QOL in domains of physical and emotional well-being (p

Published
2017

6. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Author

Lee, Sanghoon, Zhao, Li, Rojas, Christine, Bateman, Nicholas W., Yao, Hui, Lara, Olivia D., Celestino, Joseph, Morgan, Margaret B., Nguyen, Tri V., Conrads, Kelly A., Rangel, Kelly M., Dood, Robert L., Hajek, Richard A., Fawcett, Gloria L., Chu, Randy A., Wilson, Katlin, Loffredo, Jeremy L., Viollet, Coralie, Jazaeri, Amir A., Dalgard, Clifton L., Mao, Xizeng, Song, Xingzhi, Zhou, Ming, Hood, Brian L., Banskota, Nirad, Wilkerson, Matthew D., Te, Jerez, Soltis, Anthony R., Roman, Kristin, Dunn, Andrew, Cordover, David, Eterovic, Agda Karina, Liu, Jinsong, Burks, Jared K., Baggerly, Keith A., Fleming, Nicole D., Lu, Karen H., Westin, Shannon N., Coleman, Robert L., Mills, Gordon B., Casablanca, Yovanni, Zhang, Jianhua, Conrads, Thomas P., Maxwell, George L., Futreal, P. Andrew, and Sood, Anil K.

Published
2020
Full Text
View/download PDF

7. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Daver, Naval, Boumber, Yanis, Kantarjian, Hagop, Ravandi, Farhad, Cortes, Jorge, Rytting, Michael E, Kawedia, Jitesh D, Basnett, Jordan, Culotta, Kirk S, Zeng, Zhihong, Lu, Hongbo, Richie, Mary Ann, Garris, Rebecca, Xiao, Lianchun, Liu, Wenbin, Baggerly, Keith A, Jabbour, Elias, O'Brien, Susan, Burger, Jan, Bendall, Linda J, Thomas, Deborah, and Konopleva, Marina

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Hematology, Childhood Leukemia, Pediatric Cancer, Rare Diseases, Pediatric, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Child, Cyclophosphamide, Dexamethasone, Doxorubicin, Drug Monitoring, Female, Humans, Male, Middle Aged, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Recurrence, Signal Transduction, Survival Analysis, TOR Serine-Threonine Kinases, Treatment Outcome, Vincristine, Young Adult, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposePrevious studies suggest a potential therapeutic role for mTOR inhibition in lymphoid malignancies. This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL).Experimental designTwenty-four patients were treated; 15 received everolimus 5 mg/day and 9 received 10 mg/day with HyperCVAD.ResultsThe median age of patients was 25 years (range, 11-64) and median number of prior treatments was 2 (range, 1-7). Grade 3 mucositis was the dose-limiting toxicity and the maximum tolerated everolimus dose was 5 mg/day. Responses included complete remission (CR) in 6 patients (25%), CR without platelet recovery (CRp) in 1 (4%), and CR without recovery of counts (CRi) in 1 (4%), for an overall response rate of 33%. In addition, partial response (PR) was noted in 2 patients (8%). Seven of 11 patients treated in first salvage achieved CR/CRp (64%). The median OS was 29 weeks for patients in first salvage versus 15 weeks for patients in second salvage and beyond (P ≤ 0.001). A response was noted in 5 of 10 (50%) heavily pretreated T-ALL patients (median of 4 prior salvage regimens). Everolimus significantly inhibited phosphorylation of S6RP, but this did not correlate with response. No significant decreases in p4EBP1 and pAkt levels were noted. Responders had higher everolimus dose-adjusted area under the curve (P = 0.025) and lower clearance (P = 0.025) than nonresponders.ConclusionsThe combination of HyperCVAD and everolimus is well tolerated and moderately effective in relapsed ALL, specifically T-ALL.

Published
2015

10. Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology

Author

Baggerly, Keith A. and Coombes, Kevin R.

Subjects
Statistics - Applications
Abstract

High-throughput biological assays such as microarrays let us ask very detailed questions about how diseases operate, and promise to let us personalize therapy. Data processing, however, is often not described well enough to allow for exact reproduction of the results, leading to exercises in "forensic bioinformatics" where aspects of raw data and reported results are used to infer what methods must have been employed. Unfortunately, poor documentation can shift from an inconvenience to an active danger when it obscures not just methods but errors. In this report we examine several related papers purporting to use microarray-based signatures of drug sensitivity derived from cell lines to predict patient response. Patients in clinical trials are currently being allocated to treatment arms on the basis of these results. However, we show in five case studies that the results incorporate several simple errors that may be putting patients at risk. One theme that emerges is that the most common errors are simple (e.g., row or column offsets); conversely, it is our experience that the most simple errors are common. We then discuss steps we are taking to avoid such errors in our own investigations., Comment: Published in at http://dx.doi.org/10.1214/09-AOAS291 the Annals of Applied Statistics (http://www.imstat.org/aoas/) by the Institute of Mathematical Statistics (http://www.imstat.org)

Published
2010
Full Text
View/download PDF

11. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

Author

Choi, Woonyoung, Porten, Sima, Kim, Seungchan, Willis, Daniel, Plimack, Elizabeth R, Hoffman-Censits, Jean, Roth, Beat, Cheng, Tiewei, Tran, Mai, Lee, I-Ling, Melquist, Jonathan, Bondaruk, Jolanta, Majewski, Tadeusz, Zhang, Shizhen, Pretzsch, Shanna, Baggerly, Keith, Siefker-Radtke, Arlene, Czerniak, Bogdan, Dinney, Colin PN, and McConkey, David J

Subjects
Cancer, Breast Cancer, Genetics, Urologic Diseases, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Blotting, Western, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Cell Differentiation, Cell Proliferation, Cisplatin, Clinical Trials, Phase II as Topic, Cohort Studies, Doxorubicin, Drug Resistance, Neoplasm, Female, Gene Expression Profiling, Humans, Male, Methotrexate, MicroRNAs, Muscle Neoplasms, Mutation, Neoadjuvant Therapy, Neoplasm Invasiveness, Neoplasm Staging, PPAR gamma, Prognosis, RNA, Messenger, Real-Time Polymerase Chain Reaction, Receptor, Fibroblast Growth Factor, Type 3, Receptors, Estrogen, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Protein p53, Urinary Bladder Neoplasms, Vinblastine, Neurosciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. We discovered three molecular subtypes of MIBC that resembled established molecular subtypes of breast cancer. Basal MIBCs shared biomarkers with basal breast cancers and were characterized by p63 activation, squamous differentiation, and more aggressive disease at presentation. Luminal MIBCs contained features of active PPARγ and estrogen receptor transcription and were enriched with activating FGFR3 mutations and potential FGFR inhibitor sensitivity. p53-like MIBCs were consistently resistant to neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy, and all chemoresistant tumors adopted a p53-like phenotype after therapy. Our observations have important implications for prognostication, the future clinical development of targeted agents, and disease management with conventional chemotherapy.

Published
2014

12. illuminaio: An open source IDAT parsing tool for Illumina microarrays

Author

Smith, Mike L, Baggerly, Keith A, Bengtsson, Henrik, Ritchie, Matthew E, and Hansen, Kasper D

Subjects
Biochemistry and Cell Biology, Clinical Sciences, Oncology and Carcinogenesis
Abstract

The IDAT file format is used to store BeadArray data from the myriad of genomewide profiling platforms on offer from Illumina Inc. This proprietary format is output directly from the scanner and stores summary intensities for each probe-type on an array in a compact manner. A lack of open source tools to process IDAT files has hampered their uptake by the research community beyond the standard step of using the vendor's software to extract the data they contain in a human readable text format. To fill this void, we have developed the illuminaio package that parses IDAT files from any BeadArray platform, including the decryption of files from Illumina's gene expression arrays. illuminaio provides the first open-source package for this task, and will promote wider uptake of the IDAT format as a standard for sharing Illumina BeadArray data in public databases, in the same way that the CEL file serves as the standard for the Affymetrix platform.

Published
2013

19. Supplementary Figure from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

Author

McGuire, Michael H., primary, Dasari, Santosh K., primary, Yao, Hui, primary, Wen, Yunfei, primary, Mangala, Lingegowda S., primary, Bayraktar, Emine, primary, Ma, Wencai, primary, Ivan, Cristina, primary, Shoshan, Einav, primary, Wu, Sherry Y., primary, Jonasch, Eric, primary, Bar-Eli, Menashe, primary, Wang, Jing, primary, Baggerly, Keith A., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

20. Data from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

Author

McGuire, Michael H., primary, Dasari, Santosh K., primary, Yao, Hui, primary, Wen, Yunfei, primary, Mangala, Lingegowda S., primary, Bayraktar, Emine, primary, Ma, Wencai, primary, Ivan, Cristina, primary, Shoshan, Einav, primary, Wu, Sherry Y., primary, Jonasch, Eric, primary, Bar-Eli, Menashe, primary, Wang, Jing, primary, Baggerly, Keith A., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

Author

McGuire, Michael H., primary, Dasari, Santosh K., primary, Yao, Hui, primary, Wen, Yunfei, primary, Mangala, Lingegowda S., primary, Bayraktar, Emine, primary, Ma, Wencai, primary, Ivan, Cristina, primary, Shoshan, Einav, primary, Wu, Sherry Y., primary, Jonasch, Eric, primary, Bar-Eli, Menashe, primary, Wang, Jing, primary, Baggerly, Keith A., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

Author

Villar-Prados, Alejandro, primary, Wu, Sherry Y., primary, Court, Karem A., primary, Ma, Shaolin, primary, LaFargue, Christopher, primary, Chowdhury, Mamur A., primary, Engelhardt, Margaret I., primary, Ivan, Cristina, primary, Ram, Prahlad T., primary, Wang, Ying, primary, Baggerly, Keith, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Yang, Shyh-Ming, primary, Maloney, David J., primary, Yoshioka, Makoto, primary, Strovel, Jeffrey W., primary, Roszik, Jason, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

Author

Villar-Prados, Alejandro, primary, Wu, Sherry Y., primary, Court, Karem A., primary, Ma, Shaolin, primary, LaFargue, Christopher, primary, Chowdhury, Mamur A., primary, Engelhardt, Margaret I., primary, Ivan, Cristina, primary, Ram, Prahlad T., primary, Wang, Ying, primary, Baggerly, Keith, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Yang, Shyh-Ming, primary, Maloney, David J., primary, Yoshioka, Makoto, primary, Strovel, Jeffrey W., primary, Roszik, Jason, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures from Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas

Author

Jiao, Jingjing, primary, Niu, Weibo, primary, Wang, Ying, primary, Baggerly, Keith, primary, Ye, Yuanqing, primary, Wu, Xifeng, primary, Davenport, Dewitt, primary, Almeda, Jose Luis, primary, Betancourt-Garcia, Monica M., primary, Forse, R. Armour, primary, Stevenson, Heather L., primary, Watt, Gordon P., primary, McCormick, Joseph B., primary, Fisher-Hoch, Susan P., primary, and Beretta, Laura, primary

Published
2023
Full Text
View/download PDF

28. Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

Author

Villar-Prados, Alejandro, primary, Wu, Sherry Y., primary, Court, Karem A., primary, Ma, Shaolin, primary, LaFargue, Christopher, primary, Chowdhury, Mamur A., primary, Engelhardt, Margaret I., primary, Ivan, Cristina, primary, Ram, Prahlad T., primary, Wang, Ying, primary, Baggerly, Keith, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Yang, Shyh-Ming, primary, Maloney, David J., primary, Yoshioka, Makoto, primary, Strovel, Jeffrey W., primary, Roszik, Jason, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1 from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer

Author

Wen, Yunfei, primary, Wang, Ying, primary, Chelariu-Raicu, Anca, primary, Stur, Elaine, primary, Liu, Yuan, primary, Corvigno, Sara, primary, Bartsch, Faith, primary, Redfern, Lauren, primary, Zand, Behrouz, primary, Kang, Yu, primary, Liu, Jinsong, primary, Baggerly, Keith, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

Author

Villar-Prados, Alejandro, primary, Wu, Sherry Y., primary, Court, Karem A., primary, Ma, Shaolin, primary, LaFargue, Christopher, primary, Chowdhury, Mamur A., primary, Engelhardt, Margaret I., primary, Ivan, Cristina, primary, Ram, Prahlad T., primary, Wang, Ying, primary, Baggerly, Keith, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, Yang, Shyh-Ming, primary, Maloney, David J., primary, Yoshioka, Makoto, primary, Strovel, Jeffrey W., primary, Roszik, Jason, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Tables from Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas

Author

Jiao, Jingjing, primary, Niu, Weibo, primary, Wang, Ying, primary, Baggerly, Keith, primary, Ye, Yuanqing, primary, Wu, Xifeng, primary, Davenport, Dewitt, primary, Almeda, Jose Luis, primary, Betancourt-Garcia, Monica M., primary, Forse, R. Armour, primary, Stevenson, Heather L., primary, Watt, Gordon P., primary, McCormick, Joseph B., primary, Fisher-Hoch, Susan P., primary, and Beretta, Laura, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 1-3 and Figures 1-7. from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer

Author

Wen, Yunfei, primary, Wang, Ying, primary, Chelariu-Raicu, Anca, primary, Stur, Elaine, primary, Liu, Yuan, primary, Corvigno, Sara, primary, Bartsch, Faith, primary, Redfern, Lauren, primary, Zand, Behrouz, primary, Kang, Yu, primary, Liu, Jinsong, primary, Baggerly, Keith, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer

Author

Wen, Yunfei, primary, Wang, Ying, primary, Chelariu-Raicu, Anca, primary, Stur, Elaine, primary, Liu, Yuan, primary, Corvigno, Sara, primary, Bartsch, Faith, primary, Redfern, Lauren, primary, Zand, Behrouz, primary, Kang, Yu, primary, Liu, Jinsong, primary, Baggerly, Keith, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

37. Figure S1 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

Author

Liu, Tao, primary, Hu, Wei, primary, Dalton, Heather J., primary, Choi, Hyun Jin, primary, Huang, Jie, primary, Kang, Yu, primary, Pradeep, Sunila, primary, Miyake, Takahito, primary, Song, Jian H., primary, Wen, Yunfei, primary, Lu, Chunhua, primary, Pecot, Chad V., primary, Bottsford-Miller, Justin, primary, Zand, Behrouz, primary, Jennings, Nicholas B., primary, Ivan, Cristina, primary, Gallick, Gary E., primary, Baggerly, Keith A., primary, Hangauer, David G., primary, Coleman, Robert L., primary, Frumovitz, Michael, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Materials and Methods, Figures 1 - 14, Table 1 from Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer

Author

Tucker, Susan L., primary, Gharpure, Kshipra, primary, Herbrich, Shelley M., primary, Unruh, Anna K., primary, Nick, Alpa M., primary, Crane, Erin K., primary, Coleman, Robert L., primary, Guenthoer, Jamie, primary, Dalton, Heather J., primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Lopez-Berestein, Gabriel, primary, Ozpolat, Bulent, primary, Ivan, Cristina, primary, Hu, Wei, primary, Baggerly, Keith A., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

39. AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Author

Aparicio, Ana M., primary, Shen, Li, primary, Tapia, Elsa Li Ning, primary, Lu, Jing-Fang, primary, Chen, Hsiang-Chun, primary, Zhang, Jiexin, primary, Wu, Guanglin, primary, Wang, Xuemei, primary, Troncoso, Patricia, primary, Corn, Paul, primary, Thompson, Timothy C., primary, Broom, Bradley, primary, Baggerly, Keith, primary, Maity, Sankar N., primary, and Logothetis, Christopher J., primary

Published
2023
Full Text
View/download PDF

40. AVPC Molecular Signature Aparicio Supplementary Material from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Author

Aparicio, Ana M., primary, Shen, Li, primary, Tapia, Elsa Li Ning, primary, Lu, Jing-Fang, primary, Chen, Hsiang-Chun, primary, Zhang, Jiexin, primary, Wu, Guanglin, primary, Wang, Xuemei, primary, Troncoso, Patricia, primary, Corn, Paul, primary, Thompson, Timothy C., primary, Broom, Bradley, primary, Baggerly, Keith, primary, Maity, Sankar N., primary, and Logothetis, Christopher J., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure Legends from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

43. Figures S1-S10 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

Author

Wang, Zixing, primary, Kim, Tae Beom, primary, Peng, Bo, primary, Karam, Jose, primary, Creighton, Chad, primary, Joon, Aron, primary, Kawakami, Fumi, primary, Trevisan, Patricia, primary, Jonasch, Eric, primary, Chow, Chi-Wan, primary, Canales, Jaime Rodriguez, primary, Tamboli, Pheroze, primary, Tannir, Nizar, primary, Wood, Christopher, primary, Monzon, Federico, primary, Baggerly, Keith, primary, Varella-Garcia, Marileila, primary, Czerniak, Bogdan, primary, Wistuba, Ignacio, primary, Mills, Gordon, primary, Shaw, Kenna, primary, Chen, Ken, primary, and Sircar, Kanishka, primary

Published
2023
Full Text
View/download PDF

44. AVPC Molecular Signature Supplementary Tables 1-10 from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Author

Aparicio, Ana M., primary, Shen, Li, primary, Tapia, Elsa Li Ning, primary, Lu, Jing-Fang, primary, Chen, Hsiang-Chun, primary, Zhang, Jiexin, primary, Wu, Guanglin, primary, Wang, Xuemei, primary, Troncoso, Patricia, primary, Corn, Paul, primary, Thompson, Timothy C., primary, Broom, Bradley, primary, Baggerly, Keith, primary, Maity, Sankar N., primary, and Logothetis, Christopher J., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 4 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 1 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Author

Konopleva, Marina Y., primary, Walter, Roland B., primary, Faderl, Stefan H., primary, Jabbour, Elias J., primary, Zeng, Zhihong, primary, Borthakur, Gautam, primary, Huang, Xuelin, primary, Kadia, Tapan M., primary, Ruvolo, Peter P., primary, Feliu, Jennie B., primary, Lu, Hongbo, primary, Debose, LaKiesha, primary, Burger, Jan A., primary, Andreeff, Michael, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Kornblau, Steven M., primary, Doyle, L. Austin, primary, Estey, Elihu H., primary, and Kantarjian, Hagop M., primary

Published
2023
Full Text
View/download PDF

47. Information of Microarray Data from Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

Author

Masuda, Hiroko, primary, Baggerly, Keith A., primary, Wang, Ying, primary, Zhang, Ya, primary, Gonzalez-Angulo, Ana Maria, primary, Meric-Bernstam, Funda, primary, Valero, Vicente, primary, Lehmann, Brian D., primary, Pietenpol, Jennifer A., primary, Hortobagyi, Gabriel N., primary, Symmans, W. Fraser, primary, and Ueno, Naoto T., primary

Published
2023
Full Text
View/download PDF

48. Figures S1-S6; Table S1-S5 from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer

Author

Yang, Wei-Lei, primary, Gentry-Maharaj, Aleksandra, primary, Simmons, Archana, primary, Ryan, Andy, primary, Fourkala, Evangelia Ourania, primary, Lu, Zhen, primary, Baggerly, Keith A., primary, Zhao, Yang, primary, Lu, Karen H., primary, Bowtell, David, primary, Jacobs, Ian, primary, Skates, Steven J., primary, He, Wei-Wu, primary, Menon, Usha, primary, and Bast, Robert C., primary

Published
2023
Full Text
View/download PDF

49. Data from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Daver, Naval, primary, Boumber, Yanis, primary, Kantarjian, Hagop, primary, Ravandi, Farhad, primary, Cortes, Jorge, primary, Rytting, Michael E., primary, Kawedia, Jitesh D., primary, Basnett, Jordan, primary, Culotta, Kirk S., primary, Zeng, Zhihong, primary, Lu, Hongbo, primary, Richie, Mary Ann, primary, Garris, Rebecca, primary, Xiao, Lianchun, primary, Liu, Wenbin, primary, Baggerly, Keith A., primary, Jabbour, Elias, primary, O'Brien, Susan, primary, Burger, Jan, primary, Bendall, Linda J., primary, Thomas, Deborah, primary, and Konopleva, Marina, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results